Skip to main content
  • Home
  •  The Clinical Evidence Behind Pulse Field Ablation: Safe, Simple & Effective?

The Clinical Evidence Behind Pulse Field Ablation: Safe, Simple & Effective?

  • Optimising treatment

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

No ratings


This CME programme 'The Clinical Evidence Behind Pulse Field Ablation: Safe, Simple & Effective?', co-chaired by Dr Claire Martin (Royal Papworth Hospital, UK) and Prof Josef Kautzner (Charles University Medical School, Czech Republic) present and discuss a series of topics surrounding the clinical evidence behind pulsed field ablation (PFA).

Dr Vivek Reddy (The Mount Sinai Hospital, US) and Dr Boris Schmidt (Centrum Bethanien, Germany) provide an overview focusing on two clinical trials: MANIFEST-PF and EUPORIA, covering trial designs and outlining the main outcomes.

In the latter part of the programme, Dr Mattias Duytschaever (University of Ghent, Belgium) dives into the fast evolving field of PFA and a look into the different PFA systems, whilst also touching on emerging clinical data and technologies such as PULSED-AF, InspIRE & smartfIRE and ADVENT & ADVANTAGE. 

Support Statement

This programme has been supported by an unrestricted educational grant by Boston Scientific. The scientific programme has not been influenced in any way.


In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

The session ‘The Clinical Evidence Behind Pulse Field Ablation: Safe, Simple & Effective?', is accredited by the European Board for Accreditation in Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Continuing Education for Health Professionals (EBAC) and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instruction to Participants

There is no fee for taking part in this online learning activity.

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.

Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Cardiologists
  • Electrophysiologists
  • Interventionalists

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify limitations of current ablation technologies
  • Recall the advantages of pulse field ablation over other technologies
  • Summarise the design, efficacy and safety findings of relevant clinical trial data evaluating the efficacy and safety of pulse field ablation technology
  • Compare different PFA systems and emerging technologies
  • Evaluate the evolving landscape of pulse field ablation technologies
Register now Log in





Session 1 Introduction and MANIFEST PF Registry 23m 17s Vivek Reddy
Session 2 EUPORIA Registry 20m 31s Boris Schmidt
Session 3 The Fast Evolving Field of PFA 19m 26s Mattias Duytschaever
Session 1.

Introduction and MANIFEST PF Registry

Duration: 23m 17s

Speakers: Vivek Reddy

Session 2.

EUPORIA Registry

Duration: 20m 31s

Speakers: Boris Schmidt

Session 3.

The Fast Evolving Field of PFA

Duration: 19m 26s

Speakers: Mattias Duytschaever

Course Director

Claire Martin

Royal Papworth Hospital in Cambridge, UK

Dr Martin undertook undergraduate and clinical training at Cambridge University (Gonville and Caius College).

View full profile

Josef Kautzner

Institute for Clinical and Experimental Medicine, Prague, CZ

Josef Kautzner is Professor of Medicine at Charles University Medical School I in Prague, Czech Republic.

View full profile


Vivek Reddy

Icahn School of Medicine at Mount Sinai, New York, US

Dr Vivek Y. Reddy is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Director of Electrophysiology for the Mount Sinai Health System, and The Leona M. and Harry B.

View full profile

Boris Schmidt

Cardioangiologisches Centrum Bethanien, Frankfurt, Germany

Dr Boris Schmidt is a Cardiologist specialising in Electrophysiology at Cardiologisches Centrum Bethanien in Frankfurt, Germany.

View full profile

Mattias Duytschaever

St Jan Hospital, Bruges, Belgium

Dr Mattias Duytschaever obtained his medical degree in 1995 from the University of Ghent and conducted research for his PhD into the role of atrial electrical remodeling in the management of atrial fibrillation , at the University of Maastricht, The Netherlands. 

View full profile
1.00 EBAC

Related Courses

Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
  • 1.00 EBAC

Learning objectives

  • Recall prevalence of patients who are statin uncontrolled/intolerant
  • Define the additive benefit of combination treatment compared with statin intensification
  • Name the non-statin LLTs offering proven CV protection
  • Identifying patients with indication for novel non-statin therapy
  • Initiate lipid-lowering strategies proven to lower future CV events
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more